PURPOSE: To evaluate the feasibility and preliminary results of intraoperative radiotherapy (IORT) with low-energy photons as a boost in patients with early-stage oral cancer with the indications for postoperative radiotherapy. PATIENTS AND METHODS: Between 2003 and 2006, 16 patients with early-stage cancer of mobile tongue (n = 10 [63%]) or floor of the mouth (n = 6 [37%]) treated at Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland, were evaluated for IORT boost with the INTRABEAM®System (Carl Zeiss Surgical GmbH; IORT-PRS) because of the high risk of local recurrence due to positive margins on frozen pathologic section. After tumor resection, the applicator was positioned in the tumor bed. The applicator's diameter (range: 1.5-5 cm) was selected to encompass high-risk area of tumor recurrence. The dose (5 Gy, 7 Gy, or 7.5 Gy) was applied according to tumor volume and bone proximity. External-beam radiotherapy (EBRT) was provided to the tumor bed in all patients (50 Gy) and to the nodal area, when needed. Toxicity and local tumor control were assessed. RESULTS: Median follow-up was 36 months. IORT did not increase acute mucosal reaction. Local tumor control was found in all cases. Early mucosal reaction did not exceed 3 according to the RTOG scale and healed in median time of 35 days after completion of EBRT. No late adverse effects were observed. CONCLUSION: This preliminary report has demonstrated the feasibility of IORT-PRS for patients with early oral cancer with the indications for postoperative radiotherapy. This method may be considered an alternative boost technique, although additional studies are needed to establish long-term results in a larger group of patients.
PURPOSE: To evaluate the feasibility and preliminary results of intraoperative radiotherapy (IORT) with low-energy photons as a boost in patients with early-stage oral cancer with the indications for postoperative radiotherapy. PATIENTS AND METHODS: Between 2003 and 2006, 16 patients with early-stage cancer of mobile tongue (n = 10 [63%]) or floor of the mouth (n = 6 [37%]) treated at Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland, were evaluated for IORT boost with the INTRABEAM®System (Carl Zeiss Surgical GmbH; IORT-PRS) because of the high risk of local recurrence due to positive margins on frozen pathologic section. After tumor resection, the applicator was positioned in the tumor bed. The applicator's diameter (range: 1.5-5 cm) was selected to encompass high-risk area of tumor recurrence. The dose (5 Gy, 7 Gy, or 7.5 Gy) was applied according to tumor volume and bone proximity. External-beam radiotherapy (EBRT) was provided to the tumor bed in all patients (50 Gy) and to the nodal area, when needed. Toxicity and local tumor control were assessed. RESULTS: Median follow-up was 36 months. IORT did not increase acute mucosal reaction. Local tumor control was found in all cases. Early mucosal reaction did not exceed 3 according to the RTOG scale and healed in median time of 35 days after completion of EBRT. No late adverse effects were observed. CONCLUSION: This preliminary report has demonstrated the feasibility of IORT-PRS for patients with early oral cancer with the indications for postoperative radiotherapy. This method may be considered an alternative boost technique, although additional studies are needed to establish long-term results in a larger group of patients.
Authors: John A Kalapurakal; Stewart Goldman; Wendy Stellpflug; John Curran; Vythialingam Sathiaseelan; Maryanne H Marymont; Tadanori Tomita Journal: Int J Radiat Oncol Biol Phys Date: 2006-04-03 Impact factor: 7.038
Authors: L J Peters; H Goepfert; K K Ang; R M Byers; M H Maor; O Guillamondegui; W H Morrison; R S Weber; A S Garden; R A Frankenthaler Journal: Int J Radiat Oncol Biol Phys Date: 1993-04-30 Impact factor: 7.038
Authors: Barbara Belletti; Jayant S Vaidya; Sara D'Andrea; Frank Entschladen; Mario Roncadin; Francesca Lovat; Stefania Berton; Tiziana Perin; Ezio Candiani; Sonia Reccanello; Andrea Veronesi; Vincenzo Canzonieri; Mauro G Trovò; Kurt S Zaenker; Alfonso Colombatti; Gustavo Baldassarre; Samuele Massarut Journal: Clin Cancer Res Date: 2008-03-01 Impact factor: 12.531
Authors: Edwin Bölke; Gisela Schieren; Stephan Gripp; Gerald Steinbach; Matthias Peiper; Klaus Orth; Christiane Matuschek; Maximilian Pelzer; Guido Lammering; Ruud Houben; Christina Antke; Lars Christian Rump; Rodrigo Mota; Peter Arne Gerber; Patrick Schuler; Thomas K Hoffmann; Ethelyn Rusnak; Derik Hermsen; Wilfried Budach Journal: Strahlenther Onkol Date: 2011-02-24 Impact factor: 3.621